Objective: Insulin resistance can be triggered by enhanced dephosphorylation of the insulin receptor or downstream components in the insulin signaling cascade through protein tyrosine phosphatases (PTPs). Downregulating density-enhanced phosphatase-1 (DEP-1) resulted in an improved metabolic status in previous analyses. This phenotype was primarily caused by hepatic DEP-1 reduction. Methods: Here we further elucidated the role of DEP-1 in glucose homeostasis by employing a conventional knockout model to explore the specific contribution of DEP-1 in metabolic tissues. Ptprj À/À (DEP-1 deficient) and wild-type C57BL/6 mice were fed a low-fat or high-fat diet.
"Classical PTPs", a cysteine-based enzyme subgroup with strict phosphotyrosine-specificity, share the catalytic signature motif V/I-H-C-S-X-G [6] . Interestingly, PTP activity in insulin-sensitive tissues was found elevated in obese subjects [7] , while weight loss significantly reduced PTP activity [8, 9] . Among the 38 classical PTPs, only a subset of these phosphatases has been identified that target the IR kinase [10e12] . A prominent negative regulator of IR signaling is PTP1B (PTPN1) [13, 14] . PTP1B targets and dephosphorylates the IR at the sites pY1162/pY1163, thus diminishing IR activity, insulin signaling and metabolic action [13e15] . Transgenic overexpression of PTP1B in muscle resulted in insulin resistance [16] , while increased PTP1B levels were observed in insulin-resistant humans and rodents in adipose tissue and skeletal muscle [17, 18] . An inducible liver-specific PTP1B knockdown improved both lipid homeostasis and glucose tolerance in mice subjected to high-fat diet (HFD) [19] . The expression of the leukocyte common antigen-related phosphatase (LAR, PTPRF) was shown to be increased in skeletal muscle of insulin-resistant rodents/humans [8,20e22] , and overexpression of LAR in mouse skeletal muscle reduced insulin signaling and glucose uptake, leading to insulin resistance [21] . Src homology region 2 domain-containing phosphatase-1 (SHP-1, PTPN6) interferes with insulin signaling, and mice deficient for SHP-1 displayed improved IR signaling in skeletal muscle and liver [11] . Furthermore, targeting low molecular weight protein tyrosine phosphatase (LM-PTP, ACP1) also improved insulin sensitivity [23] . In contrast, muscle-specific knockout of the cytoplasmic T-Cell PTP (TC-PTP, PTPN2) failed to result in a metabolic phenotype and did not affect the development of insulin resistance in mice subjected to HFD-induced obesity [24] . These findings substantiate the notion that only specific PTPs are of regulatory importance for IR activation and insulin signaling. DEP-1/PTPRJ (also named CD148) is an ubiquitously expressed transmembrane, receptor-like PTP, initially linked to mechanisms of contact inhibition in cell growth [25] , which was later implicated in a number of physiological and pathological processes. For example, a role of DEP-1 has been established for thrombocyte function [26, 27] and in determining neointima formation after catheter-induced vascular injury [28] . Signaling of various different RTKs is negatively regulated by DEP-1, including the hepatocyte growth factor receptor cMet [29] , and the platelet-derived growth factor receptor beta [28, 30] . We recently identified DEP-1 as being upregulated in obese mice; DEP-1 was found being translocated to close proximity of the IR in liver tissues upon insulin challenge in situ [31] , and recombinant DEP-1 dephosphorylated the IR in vitro [31, 32] . Furthermore, antisense oligonucleotides against DEP-1, primarily downregulating DEP-1 in liver, improved insulin sensitivity, and reduced basal glucose level and body weight [31] . These findings suggested DEP-1 as a novel physiological regulator of IR signaling, and elevated expression of DEP-1 in insulinresponsive tissues as a possible pathophysiological mechanism for insulin resistance. In the present study, we sought to further elucidate the role of DEP-1 in insulin signaling and glucose homeostasis employing a DEP-1 deficient mouse strain. Body weight was measured twice weekly throughout the study. Food intake, respiratory exchange ratio (RER), and locomotor activity were measured using an indirect calorimetry system (LabMaster, TSE Systems; Bad Homburg, Germany) starting after the first 8 weeks of feeding. Mice were placed in the calorimetry systems for 24 h. Measurements were taken both over the entire 24 h period and during defined time periods, as outlined in the figure legends. An intraperitoneal insulin tolerance test (ITT) using a dose of 0.5 U/kg insulin (Insuman Ò Rapid, Sanofi Aventis, Berlin, Germany) and an intraperitoneal glucose tolerance test (GTT) with 1 g/kg glucose (Glucosteril, Fresenius, Bad Homburg, Germany) were carried out in 4 h and 12 h fasted mice, respectively. Tail vein blood was used for measuring glucose concentration with a glucometer (Precision Xceed, Abbott, Wiesbaden, Germany) at time points indicated. Before animals were sacrificed, serum was isolated from blood for measurement of insulin, leptin, resistin, monocyte chemotactic protein-1 (MCP-1) and interleukin 6 (IL-6) concentration by Milliplex ELISA according the manufacturer's instructions (Millipore, Schwalbach, Germany). Only valid values above the detection limit were used in the analyses, and numbers of included animals per parameter are stated in the figure legend. Systolic blood pressure was recorded by tail-cuff measurements (Power Lab 4/20 with tail-cuff MLT125/M, both from ADInstruments, Spechbach, Germany). For each mouse between three and eight separate blood pressure values were recorded within a period of 20e60 min between 09:00 a.m. and 12:00 p.m., and the mean was calculated for each mouse and group.
MATERIALS AND METHODS

Animal model
Protein tyrosine phosphatase activity
Activity of DEP-1 by using a radioactive labeled peptide was measured after immunoprecipitation with anti-DEP-1 (AF1934, 1 mg per condition, R&D Systems, Wiesbaden, Germany) in different metabolic tissues as described elsewhere in Ref. [31] . In order to minimize potential in vitro-induced oxidation of PTPs and to determine total DEP-1 activity as a measure of DEP-1 expression, analyses were performed including addition of 50 mM dithiothreitol (DTT) to immunoprecipitates.
Quantitative real-time PCR (qRT-PCR)
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instruction for purification from cells and tissue (soleus skeletal muscle). Synthesis of cDNA was performed with SuperScript Ò II (Invitrogen, Karlsruhe, Germany). RT-PCR was performed with SybrGreen (Applied Biosystems, Darmstadt, Germany) in duplicate per condition. The expression of analyzed genes was normalized to the average expression of the housekeeping gene Rn18s. The following primer sequences (final concentrations 100 nmol/l) were used (forward and reverse, respectively): 
Glucose uptake in cells
Myotubes were transfected and left resting for 48 h followed by serumfree starvation overnight. Cells were incubated for 1 h in glucose deficient medium. Insulin (100 nmol/l) was added for 15 min followed by addition of deoxy-D-glucose (Sigma, Taufkirchen, Deutschland) and
Germany) at a final concentration of 100 mmol/l for 30 min. The uptake was stopped by two washing steps with PBS, and cell lysis was carried out in 50 mmol/l NaOH. Uptake of radioactively labelled glucose was measured in a scintillation counter. Results were normalized to unstimulated cells transfected either with non-targeting siRNA or DEP-1 siRNA, and are presented as percent of the corresponding treatment procedure.
Glucose uptake in muscle tissue
Paired soleus muscles were dissected in deep anesthesia (Ketamin/ Xylazine 100 mg/kg/12 mg/kg) and subsequently placed in glass-vials for two incubation steps with continuous shaking in a heated (35 C) water bath. One muscle from each pair was incubated without insulin (basal), and the contralateral muscle was incubated with 5 mU/ml insulin during both incubation steps. First, muscles were incubated in glass vials containing 0.5 ml of pregassed Krebs-Henseleit buffer (KHB; 95% O 2 -5% CO 2 for 15 min at 4 C) supplemented with 0.1% bovine serum albumin, 2 mM sodium pyruvate, 6 mM mannitol, and 0 (basal), or 5 mU/ml insulin for 30 min. After the initial equilibration step, each muscle was transferred to a second glass vial containing 0.5 ml of KHBeBSA solution supplemented with 2 mM sodium pyruvate, the same insulin concentration used in the previous step, 1 mM 2-deoxyglucose (2-DG) (including a final specific activity of 2.25 mCi/ mmol 2-deoxy-[ 3 H]glucose), and 6 mM mannitol (including a final specific activity of 0.022 mCi/mmol [ 14 C]mannitol) for 15 min. Thereafter, muscles were rapidly blotted on filter paper moistened with ice-cold KHBeBSA, trimmed, freeze-clamped in liquid nitrogen and stored at À80 C for later processing and analysis. Frozen muscles used for glucose uptake were weighed and homogenized in 0.3 M perchloric acid for 3 Â 4 min. Homogenates were incubated for 10 min at 95 C, centrifuged for 15 min at 15,000 g to remove insoluble material. 3 H and 14 C disintegrations per minute were measured by a liquid scintillation counter and 2-DG uptake was calculated as described in Ref. [34] .
Islets studies
Frozen pancreas sections (5 mm) were mounted on SuperFrost Plus slides (R. Langenbrinck, Emmendingen, Germany). Sections were immunostained with primary anti-insulin antibody (MOB234, 1:200, BIOTREND Chemikalien GmbH, Cologne, Germany), with a biotinylated secondary antibody (anti-mouse, E0464, 1:1000; Dako, Hamburg, Germany) and by using the Vectastain ABC kit PK-6100 (Vector, Burlingame, CA, USA), the peroxidase kit ARK (Dako, Hamburg, Germany), and AEC solution (Sigma, Taufkirchen, Deutschland), and were counterstained with hematoxylin. The relative area of beta cells was determined as the percentage of pancreatic area occupied by insulin immunoreactive cells. Images of stained sections were analyzed using ImageJ 1.48.
Statistical analysis
Statistical differences between the groups were determined using twoway ANOVA analysis as well as the non-parametric ManneWhitney U test and the parametric unpaired Student's t test using SPSS Statistics 21. The data are expressed as means AE SEM, and p < 0.05 was considered statistically significant.
RESULTS
DEP-1 expression in metabolic tissues and characterization of
The expression of DEP-1 was analyzed in liver, skeletal muscle and adipose tissue from wild-type mice applying activity measurements under reducing conditions, as outlined in the Materials and methods section. The results revealed DEP-1 being five-fold higher expressed in adipose tissue and eight-fold higher expressed in liver compared to DEP-1 skeletal muscle ( Figure 1A ). After genotyping, activity assays along with immunoblotting were applied to confirm the absence of DEP-1 in Ptprj À/À mice ( Figure 1BeD ). As shown, DEP-1 protein and activity were undetectable in liver tissue of knockout mice.
Enhanced insulin sensitivity in Ptprj
We first assessed the effect DEP-1 deficiency on body weight under either LFD or HFD for 8 weeks, which represented the time period before metabolic phenotyping was performed. As depicted in Figure 2A only a slight decrease in body weight in Ptprj À/À mice was detectable in both diets compared to wild-type mice, which did not reach statistical significance. Knockout of DEP-1 had no influence on heart-, kidney-, liver-and spleen weight, neither at LFD nor at HFD, while perirenal fat was lower in LFD fed Ptprj À/À mice (Supplementary Table 2 ). Epididymal fat weight was significantly higher in Ptprj In liver tissue, we detected a tendency of enhanced IR phosphorylation after insulin challenge in Ptprj À/À mice, however, without any evidences of site-selectivity ( Figure 3A) . Moreover, we detected a significant increase in insulin-induced Akt phosphorylation at site Ser Thus, DEP-1 deficiency leads to enhanced insulin signaling shown by higher Akt phosphorylation.
Increased glucose uptake in skeletal muscle
The improvement of insulin sensitivity and glucose tolerance, as well as increased phosphorylation levels of Akt in Ptprj À/À mice, notably in skeletal muscle, strongly suggested a cell-autonomous role of DEP-1 for negative regulation of insulin signaling. To confirm the presumed regulatory function, we first assessed insulin-stimulated glucose uptake in cultured skeletal muscle cells in vitro. DEP-1 depletion in these cells was performed by siRNA-mediated downregulation. To confirm the efficiency of DEP-1 depletion we analyzed transcript levels of DEP-1. We achieved a downregulation of w77%, which was not counterregulated by changes in PTP1B and IR transcripts ( Figure 6A) . Also, the gene expression of the glucose transporter (GLUT1 and GLUT4) was unaffected by DEP-1 downregulation ( Figure 6A ). The incorporation of Original article
We then assessed glucose uptake using isolated soleus muscle for ex vivo analyses. These experiments revealed that insulin stimulation in skeletal muscle derived from Ptprj À/À mice resulted in a more pronounced stimulation of 2-DG uptake as compared with wild-type tissues ( Figure 6C ). While in wild-type animals there was only a trend of increased 2-DG uptake with insulin, this effect became significant in the knockout tissues, which was not due to differences in GLUT1 and GLUT4 gene expression in the soleus muscle between wild-type and Ptprj À/À mice (data not shown). These findings are consistent with the improved GTT in Ptprj À/À mice.
3.5. DEP-1 knockout affects serum parameters and blood pressure In addition to the improved metabolic phenotype, serum parameters were also analyzed to assess a potential impact of DEP-1 deficiency (Figure 7AeE) . Leptin, shown to be elevated in obesity, was significantly reduced in Ptprj À/À mice at both LFD and HFD compared to wild-type animals. Serum IL-6 and insulin levels appeared lower in Ptprj À/À mice under HFD, yet these differences were not statistically significant. Resistin and MCP-1, adipokines relevant for progression of insulin resistance, were not affected by DEP-1 knockout, but showed a characteristic HFD-induced increase. Furthermore, HFD fed Ptprj À/À mice were characterized by significantly reduced systolic blood pressure, recorded during the day time, compared to wild-type mice ( Figure 7F ). Interestingly, we detected a significantly reduced beta cell area in the pancreas of HFD-treated knockout mice compared with wild-type littermates ( Figure 7G ,H). Such differences between the two genotypes were not detected in LFD fed mice. Importantly, pancreatic tissue from mice of both diets in WT and Ptprj À/À animals was not characterized by altered apoptosis, as revealed by measuring Bax/Bcl2 ratios ( Figure 7I ). Taken together, Ptprj À/À mice appeared to have lower leptin levels, and deficiency in DEP-1 protected against HFD-induced pancreatic islet increase, consistent with lower insulin levels and the improved metabolic phenotype.
DISCUSSION
As the main finding of this study, we could establish the transmembrane PTP DEP-1/PTPRJ as a novel regulator of insulin resistance in vivo. Ptprj À/À mice subjected to LFD or HFD exhibited an improved metabolic phenotype, demonstrated by an enhancement in insulin sensitivity, glucose tolerance, reduced leptin serum levels and an increased RER. In addition to the systemic effects, DEP-1 deficiency resulted also in enhanced insulin signaling in liver, skeletal muscle and adipose tissue. Moreover, we could show that blood pressure in Ptprj À/ À mice fed an HFD was significantly reduced. Experiments with DEP-1 depleted skeletal muscle cells in vitro and soleus muscle from mice revealed increased glucose uptake. A large body of evidence has shown that PTPs are substantially involved in type 2 diabetes and insulin resistance [12, 35] . In particular, the role of PTP1B is well characterized by using different knockout models [10, 13, 14] demonstrating PTP1B À/À mice being resistant to HFD-induced insulin resistance. While the effects of DEP-1 deficiency observed in our study were clearly milder, overall DEP-1 seems to act in a manner comparable to PTP1B in this context, revealing some further redundancy in control of insulin signaling. Interestingly, DEP-1 levels were increased in HFD fed mice [31] . DEP-1 deficiency resulted in significantly enhanced insulin sensitivity. Basal fastened glucose levels were slightly, but not significantly lower in Ptprj À/À mice in both diets. While glucose tolerance was also improved at defined time points, however, this did only translate into a minor tendency towards lower AUC glucose levels. Effects on glucose challenge were not observed using antisense oligonucleotides against DEP-1 [31] , which indicates the importance of complete DEP-1 deficiency in additional insulin sensitive tissues to observe this phenotype. DEP-1 knockout in HFD fed mice resulted only in slightly reduced body weight. Ptprj À/À mice were characterized by more epididymal fat mass. This was in contrast to a decrease in body weight and a concomitant decrease in epididymal fat mass being observed in DEP-1 antisense oligonucleotides treated mice [31] . Counter-regulation of gene expression induced by complete DEP-1 depletion might be responsible for the increased epididymal fat mass. Nonetheless, improved insulin sensitivity is not mandatory associated with body weight reduction. The lack of impact of DEP-1 deficiency on body weight is reminiscent of mice with a tissue specific PTP1B depletion in muscle [36] , adipocytes [37] , or liver [38] . The latter mice were not affected in body weight but still showed increased insulin sensitivity. Further, insulin sensitization by glitazones is accompanied by increased fat mass caused by fat-redistribution [39, 40] , which may also explain decreases in liver weight in HFD fed Ptprj À/-mice.
Metabolic phenotyping performed by LabMaster analysis substantiated the improved phenotype in Ptprj À/À mice. In general, lower RER in the animal model used has previously been shown in mice subjected to HFD, demonstrating higher fat oxidation in combination with reduced carbohydrate consumption. In addition, RER has been shown to positively correlate with insulin sensitivity. Indeed, changes in both body composition and nutrient utilization closely impact on changes of the RER. In this regard, the observed increase in RER strongly suggests a direct result of the Ptprj knockout. Further, altered RER was associated with a slight, but insignificant increase of motility, whereas food intake in wild-type and knockout mice was unchanged in the individual diets. This was also evident when those time periods were subanalyzed, where significant differences in RER were detected (12:00 a.m.e03:00 a.m. for LFD fed mice, and 03:00 a.m.e06:00 a.m. for HFD fed mice). These data underline the significant impact of DEP-1 and diet on energy substrate utilization, possibly due to changes in insulin signaling, associated with enhanced glucose oxidation. No clear evidence of general or site-selective hyperphosphorylation in Ptprj À/À mice was detectable after insulin challenge. On the one hand, this is in line with the relatively low substrate specificity of DEP-1 in vitro described earlier in Ref. [41] . However, the kinetics by which PTPs regulate IR and IR-substrate-1 phosphorylation are transient and depend on the tissues analyzed. Potentially, time points other than 2 min after insulin injection would unravel altered IR phosphorylation in DEP-1 deficient mice in metabolic tissues. It is, however, likewise possible that the effect of DEP-1 deficiency mainly affects downstream events in insulin signaling rather than receptor phosphorylation itself. isolation and blotting procedures may slightly vary. Moreover, the phosphorylation of both sites was suggested to be regulated independently [42, 43] , necessary for full kinase activity, and only in skeletal muscle an increase in both Ser 473 and Thr 308 phosphorylation in Ptprj À/À mice was detected in each diet.
We detected improved insulin resistance in Ptprj À/À mice being accompanied by reduced leptin levels in both LFD and HFD fed mice. This is in accordance with antisense oligonucleotide-induced DEP-1 reduction in HFD mice lowering leptin [31] . Elevated in obesity, leptin may contribute to obesity-associated hypertension and increased heart rate [44] . Furthermore, interaction of PTP1B, another crucial phosphatase in insulin signaling, with leptin signaling in the hypothalamus has been demonstrated [45, 46] . While HFD fed wild-type mice had only slightly higher blood pressure, HFD fed Ptprj À/À mice were characterized by significantly reduced blood pressure, possibly driven, at least partly, by reduced serum leptin levels. In a similar way, also deletion of PTP1B has been shown to result in blood pressure reduction, substantiating PTPs crucially impacting on both metabolic parameters and cardiovascular regulation [47] . Fat mass is considered to be positively correlated with leptin levels. However, leptin concentration depends on the duration of HFD feeding in rodents and is independent of fat mass gain [48] . The reduced leptin levels in Ptprj À/À mice in both diets, however, might suggest a direct role of DEP-1 in leptin signaling. Blood pressure measurements were performed during the day time. Thus, potentially different nocturnal/diurnal regulation as well as a shift in mean arterial blood pressure distribution, which was demonstrated in obese PTP1B knockout mice [47] , cannot be ruled out.
Insulin resistance is associated with expansion of beta cell mass. In accordance, HFD wild-type mice were characterized by increased pancreatic beta cell area, which was not accompanied by altered apoptosis, compared to lean LFD animals. While we did not measure insulin secretion during glucose challenge, lower basal insulin levels were detected in HFD-treated Ptprj À/À mice. This is in line with significantly reduced cross-sectional beta cell area, further supporting that DEP-1 deficiency attenuates insulin resistance. Our results identified a metabolic role of DEP-1 in a conventional knockout model impacting insulin signaling (depicted in Figure 8 ) in lean and obese mice. It should be noted, however, that DEP-1 also functions as a tumor suppressor described in several cancer cells [49, 50] . Despite this, Ptprj À/À mice used in our study were not characterized by spontaneous tumor growth or other obvious abnormalities, as also described by other investigators [50] . The function of DEP-1 as a negative regulator in insulin signaling previously shown in liver tissue [31] was further extended to the glucose utilizing tissues skeletal muscle and fat. Individual metabolic tissues, including skeletal muscle, adipose tissue, and liver contribute to the overall observed metabolic improvement in Ptprj À/À mice, and this phenotype seems not to be primarily based only on the skeletal muscle. Other factors may have influenced the demonstrated phenotype, since stronger metabolic effects could have been expected as a result of the enhanced insulin signaling in adipose tissue, skeletal muscle, and liver. The improvement of metabolic parameters in Ptprj À/À mice independent of the applied diet e with higher effects in obese mice e suggests that DEP-1 is, at least partly, a direct metabolic regulator. Together with increased glucose uptake and reduced blood pressure . This ultimately leads to facilitated glucose uptake through glucose transporters (for mechanistic illustration two transporters are shown on the right hand side), suggesting DEP-1 as potential novel drug target in insulin resistance.
Original article after DEP-1 depletion a broad range of cardiovascular-metabolic improvements were achieved. Therefore, DEP-1 might be a promising target for the treatment of insulin resistance as well as metabolic and cardiovascular disorders.
CONCLUSIONS
Insulin resistance represents the main factor for developing type 2 diabetes in obese patients. A better understanding of the underlying molecular mechanisms of insulin resistance is highly warranted due to the worldwide increase of type 2 diabetics. A subset of protein tyrosine phosphatases (PTPs) targets the insulin receptor and impacts on insulin sensitivity and metabolic disease. This study aimed at establishing the PTP DEP-1 as new negative regulator in insulin signaling. Taken together, here we report for the first time that a conventional knockout of DEP-1 results in an improved metabolic phenotype in mice, characterized in particular by enhanced insulin sensitivity and insulin signaling. Further, knockdown of DEP-1 in skeletal muscle cells leads to an increased insulin-induced glucose uptake. Our findings support the notion of DEP-1 as a novel negative regulator of insulin signaling, thus representing a potential target for the treatment of insulin resistance and type 2 diabetes.
